Posttranscriptional regulation of Galectin-3 by miR-128 contributes to colorectal cancer progression

Weiqun Lu; Jia Wang; Guohua Yang; Nanrong Yu; Zhiliang Huang; Houwei Xu; Jianchang Li; Jiliang Qiu; Xiang Zeng; Shicai Chen; Nan Li; Haiying Liu

doi:10.18632/oncotarget.14839

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2018; 9:12535.

Posttranscriptional regulation of Galectin-3 by miR-128 contributes to colorectal cancer progression

Weiqun Lu, Jia Wang, Guohua Yang, Nanrong Yu, Zhiliang Huang, Houwei Xu, Jianchang Li, Jiliang Qiu, Xiang Zeng, Shicai Chen, Nan Li and Haiying Liu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:15242-15251. https://doi.org/10.18632/oncotarget.14839

Metrics: PDF 2127 views | HTML 2446 views | ?

Abstract

Weiqun Lu1,*, Jia Wang1,*, Guohua Yang1, Nanrong Yu1, Zhiliang Huang1, Houwei Xu1, Jianchang Li1, Jiliang Qiu1, Xiang Zeng1, Shicai Chen1, Nan Li1, Haiying Liu1

1Department of Gastrointestinal Neoplasms Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, Guangdong, China

*These authors contributed equally to this work

Correspondence to:

Nan Li, email: [email protected]

Haiying Liu, email: [email protected]

Keywords: colorectal cancer, Galectin-3, miR-128, cancer progression

Received: December 06, 2016 Accepted: January 17, 2017 Published: January 27, 2017

ABSTRACT

Here we demonstrated that Galectin-3 protein level was frequently up-regulated in colorectal cancer (CRC) cells and tissues. Galectin-3 up-regulation correlated with CRC progression and predicted a shorter overall survival of CRC patients. Galectin-3 overexpression attenuated the chemo-sensitivity of cancer cells, but enhanced the potential invasiveness. To explore the mechanism for Galectin-3 dysregulation, we found that miR-128 level was frequently down-regulated in CRC and negatively correlated with Galectin-3 level. Using bioinformatics analysis and experimental validation, we showed that miR-128 could directly target Galectin-3 to repress its protein level. MiR-128 decrease associated with CRC progression and predicted a worse overall survival of CRC patients. Ectopic miR-128 expression enhanced the chemo-sensitivity of CRC cells in vitro and in vivo, and inhibited the potential invasiveness. Galectin-3 expression impaired the cancer suppressive effects of miR-128. These data highlighted the role of miR-128/Galectin-3 axis in colorectal cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14839

Publication Alerts

Research Papers:

Posttranscriptional regulation of Galectin-3 by miR-128 contributes to colorectal cancer progression

Abstract